INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest

INmune Bio, Inc. (NASDAQ:INMB) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totalling 2,830,000 shares, a growth of 5.6% from the September 30th total of 2,680,000 shares. Based on an average daily trading volume, of 225,300 shares, the short-interest ratio is presently 12.6 days.

INmune Bio Stock Up 3.2 %

Shares of INMB stock opened at $6.04 on Friday. The firm has a market cap of $119.35 million, a P/E ratio of -2.93 and a beta of 1.85. The company has a 50 day moving average of $5.65 and a 200-day moving average of $7.81. INmune Bio has a 12-month low of $4.78 and a 12-month high of $14.74.

INmune Bio (NASDAQ:INMB) last issued its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. As a group, equities analysts expect that INmune Bio will post -2.14 EPS for the current year.

Insider Buying and Selling at INmune Bio

In related news, CFO David J. Moss purchased 7,690 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the purchase, the chief financial officer now owns 1,275,869 shares of the company’s stock, valued at approximately $8,140,044.22. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CFO David J. Moss acquired 7,690 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the purchase, the chief financial officer now owns 1,275,869 shares in the company, valued at approximately $8,140,044.22. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Raymond Joseph Tesi bought 15,380 shares of INmune Bio stock in a transaction dated Thursday, September 12th. The stock was purchased at an average price of $6.38 per share, with a total value of $98,124.40. Following the purchase, the chief executive officer now owns 1,554,106 shares in the company, valued at approximately $9,915,196.28. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 33,070 shares of company stock valued at $200,087. Corporate insiders own 35.20% of the company’s stock.

Institutional Investors Weigh In On INmune Bio

Several large investors have recently added to or reduced their stakes in the company. Financial Advocates Investment Management grew its stake in INmune Bio by 17.4% in the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after buying an additional 2,000 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of INmune Bio in the second quarter valued at $121,000. Fermata Advisors LLC raised its stake in shares of INmune Bio by 8.5% during the 2nd quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock valued at $301,000 after purchasing an additional 2,689 shares during the period. Westside Investment Management Inc. lifted its holdings in INmune Bio by 31.8% during the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after purchasing an additional 10,950 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in INmune Bio by 124.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after purchasing an additional 32,511 shares during the period. Hedge funds and other institutional investors own 12.72% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Raymond James began coverage on INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.00 target price on the stock. Scotiabank started coverage on INmune Bio in a research report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective on the stock. Finally, Alliance Global Partners assumed coverage on INmune Bio in a research note on Monday, October 21st. They set a “buy” rating and a $20.00 target price on the stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.